Lords Chamber
Finance Bill
2nd reading - Wed 21 Feb 2024
HM Treasury

Mentions:
1: Baroness Vere of Norbiton (Con - Life peer) The British Medical Association described it as“potentially transformative for the NHS”,because many - Speech Link
2: Lord Davies of Brixton (Lab - Life peer) abolition of the lifetime allowance would mean there would be 15,000 more people in work, not least in the medical - Speech Link
3: Lord Leigh of Hurley (Con - Life peer) They are two different sources of income and wealth, and therefore deserve different tax treatments, - Speech Link
4: Baroness Vere of Norbiton (Con - Life peer) The Government’s economic response to the coronavirus pandemic was made possible through the powerful - Speech Link

---

Select Committee

First Report - The antimicrobial potential of bacteriophages

Report Jan. 03 2024

Committee: Science, Innovation and Technology Committee

Found: Phages have been described as a ‘personalised medicine’—a group of treatments adapted to each patient

---

---

Written Question

Coronavirus: Medical Treatments

Wednesday 22nd November 2023

Asked by: Lord Mendelsohn (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that the stock of approved antiviral treatments of COVID-19, including those recommended by the National Institute for Health and Care Excellence in August are made readily available to all vulnerable patients.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The stock of COVID-19 antivirals owned by the Department is available to those who are eligible for treatment in line with an interim clinical commissioning policy for England and the Devolved Nations or National Institute for Health and Care Excellence (NICE) recommendations. Stocks are distributed in England in response to orders received from community pharmacies and National Health Service secondary care trusts who operate under arrangements put in place by the relevant NHS Commissioning Boards. Proportionate allocations have been made to the Devolved Nations and detailed distribution arrangements lie within the remit of the respective national systems.

---

Select Committee

Care Quality Commission

UKR0030 - UK Regulators

Written Evidence Dec. 13 2023

Inquiry: UK Regulators
Inquiry Status: Closed
Committee: Industry and Regulators Committee

Found: sector specific reports such as our annual reporting against our work under the Ionising Radiation (Medical

---

Select Committee

Second Report - Assisted Dying/Assisted Suicide

Report Feb. 29 2024

Committee: Health and Social Care Committee (Department: Department of Health and Social Care)

Found: During the Covid-19 pandemic, the Health Protection (Coronavirus, Restrictions) (England) Regulations

---

Select Committee

Second Report - Humanitarian situation in Gaza

Report Mar. 01 2024

Committee: International Development Committee (Department: Department for International Development)

Found: Medical care in Gaza and ongoing healthcare 42. The healthcare system in Gaza is falling apart.

---

Non-Departmental Publication (Guidance and Regulation)
Advisory Committee on Clinical Impact Awards

Nov. 28 2023

Source Page: Clinical Impact Awards 2022: personal statements
Document: Personal statements from new Clinical Impact Award holders in the 2022 round (PDF)

Found: We have grown our team, delivered new treatments and pathway improvements.

---

Written Question

Coronavirus: Drugs and Medical Treatments

Tuesday 30th January 2024

Asked by: Andrew Bridgen (Independent - North West Leicestershire)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the guidance by NICE entitled Covid-19 rapid guideline: managing symptoms (including at the end of life) in the community, NG163, published on 3 April 2020, which medical experts were consulted during the commissioning process.

Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)

The National Institute for Health and Care Excellence (NICE) guideline NG163, published in 2020, was commissioned in accordance with an established agreement between NHS England and NICE. The focus at that time was given to providing rapid guidance on the management of affected patients with COVID-19. The following organisations were consulted on the guideline:

- Association for Palliative Medicine;

- Palliative Care Formulary;

- Wolfson Palliative Care Research Centre;

- Cicely Saunders Institute;

- NHS England;

- ICU Steps;

- Macmillan Cancer Support;

- Marie Curie;

- National Audit for Care at the End of Life;

- Palliative Care for Wales;

- Royal College of General Practitioners;

- Royal College of Physicians; and

- Sue Ryder.

The following organisations provided general practice consultation on the guidance:

- NICE GP Reference Group; and

- RCGP Network.

A number of NICE’s COVID-19 rapid guidelines were subsequently incorporated into a single guideline, NG191, for the management of COVID-19 in children and adults. The list of panel members for this guideline is available at the following link:

https://www.nice.org.uk/guidance/ng191/documents/register-of-interests-2

---

Select Committee

Astellas Pharma Ltd.

FCR0037 - Future cancer

Written Evidence Jun. 28 2023

Inquiry: Future cancer
Inquiry Status: Closed
Committee: Health and Social Care Committee (Department: Department of Health and Social Care)

Found: In gastric cancer, we are committed to the development of treatments that bring new therapeutic

---